Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Health-related quality of life (HRQoL) outcomes in the RATIONALE-305 study.

被引：0

作者：

Cruz-Correa, Marcia

Xu, Rui-Hua

Moehler, Markus H.

Oh, Do-Youn

Kato, Ken

Spigel, David R.

Arkenau, Hendrik-Tobias

Tabernero, Josep

Zimina, Anastasia V.

Bai, Yuxian

Shi, Jianhua

Lee, Keun-Wook

Hirano, Hidekazu

Wyrwicz, Lucjan S.

Pazo Cid, Roberto

Xu, Hui

Sheng, Tao

Barnes, Gisoo

机构：

[1] Univ Puerto Rico, Sch Med, San Juan, PR 00936 USA

[2] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China

[3] Johannes Gutenberg Univ Clin, Dept Internal Med, Mainz, Germany

[4] Seoul Natl Univ Hosp, Dept Internal Med, Div Med Oncol, Seoul, South Korea

[5] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea

[6] Natl Canc Ctr, Tokyo, Japan

[7] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA

[8] Sarah Cannon Res, London, England

[9] Vall DHebron Univ Hosp & Inst Oncol VHIO, Barcelona, Spain

[10] BHI Omsk Reg Clin Oncol Dispensary, Omsk, Russia

[11] Harbin Med Univ Canc Hosp, Dept Gastrointestinal Oncol, Harbin, Peoples R China

[12] Linyi Canc Hosp, Dept Med Oncol, Linyi, Peoples R China

[13] Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Seongnam, South Korea

[14] Natl Canc Ctr Hosp, Dept Gastrointestinal Med Oncol, Chuo City, Japan

[15] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[16] Hosp Univ Miguel Servet, Zaragoza, Spain

[17] BeiGene Beijing Co Ltd, Beijing, Peoples R China

[18] BeiGene USA Inc, San Mateo, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期

关键词：

261-566-148; 613-135-2370-7650-2700; 130-274-2403; 613-302-309; 613-302-312-303; 17; 9; 3; 2; 2424; 1704;

D O I：

10.1200/JCO.2024.42.3_suppl.290

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：290 / 290

页数：1

共 50 条

[31] Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N plus C) versus chemo (C)
Moehler, M.
Wyrwicz, L.
Chen, C.
Davenport, E.
Wang, J.
Nathani, R.
Kondo, K.
Elimova, E.
ANNALS OF ONCOLOGY, 2023, 34 : S185 - S185
[32] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/ gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Additional analyses from 4year (y) follow-up (FU) of CheckMate 649
Wyrwicz, L. S.
Shitara, K.
Moehler, M.
Ajani, J. A.
Shen, L.
Garrido, M.
Gallardo Araneda, C. E.
Yamaguchi, K.
Cleary, J.
Elimova, E.
Bruges Maya, R.
Karamouzis, M. V.
Skoczylas, T.
Bragagnoli, A. C.
Liu, T.
Tehfe, M.
Feeney, K.
Wang, R.
Zhang, J.
Janjigian, Y. Y.
ANNALS OF ONCOLOGY, 2024, 35 : S169 - S170
[33] Randomized, global, phase III study of tislelizumab (TIS) plus chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup
Kato, K.
Yoon, H.
Raymond, E.
Hubner, R.
Shu, Y.
Pan, Y.
Park, S. R.
Ping, L.
Jiang, Y.
Zhang, J.
Wu, X.
Yao, Y.
Shen, L.
Kojima, T.
Lin, C-Y.
Wang, L.
Tao, A.
Peng, Y.
Li, L.
Xu, J.
ANNALS OF ONCOLOGY, 2022, 33 : S1458 - S1458
[34] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis with 3-year follow-up.
Shen, Lin
Bai, Yuxian
Lin, Xiaoyan
Li, Wei
Wang, Jufeng
Zhang, Xiaochun
Pan, Hongming
Bai, Chunmei
Bai, Li
Cheng, Ying
Zhang, Jingdong
Zhong, Haijun
Ba, Yi
Hu, Wenwei
Xu, Rui-Hua
Guo, Weijian
Qin, Shukui
Wang, Rui
Sullivan, Kendall
Liu, Tianshu
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 353 - 353
[35] RATIONALE-304 long-term outcomes: First-line tislelizumab (TIS) plus chemotherapy (chemo) vs chemo for locally advanced or metastatic non-squamous (NSQ) NSCLC
Ma, Z.
Yu, Y.
Yu, X.
Li, X.
Cui, J.
Wang, D.
Wang, X.
Wu, J.
Huang, D.
Li, G.
Zhao, N.
Liang, L.
Song, M.
Lu, S.
ANNALS OF ONCOLOGY, 2024, 35 : S1637 - S1637
[36] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 4-year (yr) follow-up
Shen, Lin
Bai, Yuxian
Lin, Xiaoyan
Li, Wei
Wang, Jufeng
Zhang, Xiaochun
Pan, Hongming
Bai, Chunmei
Bai, Li
Cheng, Ying
Zhang, Jingdong
Zhong, Haijun
Ba, Yi
Hu, Wenwei
Xu, Rui-Hua
Guo, Weijian
Qin, Shukui
Wang, Rui
McCraith, Stephen
Liu, Tianshu
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 318 - 318
[37] Health-related quality of life (HRQoL) impact of pembrolizumab (P) versus chemotherapy (C) as first-line (1L) treatment in PD-L1-positive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Van Cutsem, E.
Valderrama, A.
Bang, Y-J.
Fuchs, C.
Shitara, K.
Janjigian, Y. Y.
Qin, S.
Larson, T.
Shankaran, V.
Stein, S.
Norquist, J. M.
Kher, U.
Shah, S.
Alsina, M.
ANNALS OF ONCOLOGY, 2019, 30 : 879 - 879
[38] Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N plus C) vs (C)
Moehler, Markus
Wyrwicz, Lucjan
Chen, Clara
Davenport, Eric
Wang, Jinyi
Nathani, Raheel
Kondo, Kaoru
Elimova, Elena
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 65 - 65
[39] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649.
Shen, Lin
Bai, Yuxian
Lin, Xiaoyan
Li, Wei
Wang, Jufeng
Zhang, Xiaochun
Pan, Hongming
Bai, Chunmei
Bai, Li
Cheng, Ying
Zhang, Jingdong
Zhong, Haijun
Ba, Yi
Hu, Wenwei
Xu, Rui-Hua
Guo, Weijian
Qin, Shukui
Hu, Nan
McCraith, Stephen
Liu, Tianshu
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 392 - 392
[40] Response characteristics of tislelizumab (TIS) plus chemotherapy (chemo) in first-line (1L) treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): A post hoc analysis of RATIONALE-306.
Li, Yi
Zhao, Chuanhua
Liu, Rongrui
Xu, Sheng
Miao, Xiaojie
Xu, Jianming
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 413 - 413

← 1 2 3 4 5 →